Interventional Pulmonology Market Outlook:
Interventional Pulmonology Market size was over USD 3.3 billion in 2024 and is estimated to reach USD 6.1 billion by the end of 2034, expanding at a CAGR of 7.4% during the forecast timeline, i.e., 2025-2034. In 2025, the industry size of interventional pulmonology is assessed at USD 3.7 billion.
The increased incidence of respiratory ailments is primarily fueling a surge in the market. Testifying to this demographic shift, the World Health Organization (WHO) revealed that, in 2023, more than 384.4 million people around the world were suffering from chronic obstructive pulmonary disease (COPD). It also marked the annual population of newly diagnosed lung cancer-afflicted residents to hit 2.6 million. Besides, the rising demand for minimally invasive surgeries (MIS) led to 1.6 million bronchoscopies performed yearly in hospitals and ASCs across the U.S., as per the Centers for Disease Control and Prevention (CDC). This reflects the increasing adoption of bronchoscopes, airway stents, and pleural catheters for advanced respiratory care.
The supply chain of the market is highly specialized, where the manufacturing of 70.4% of flexible bronchoscopes is concentrated in Japan, the U.S., and Germany. On the other hand, 40.4% of essential components, including medical-grade silicone, originate from China and India, according to the International Trade Commission (ITC). However, the inflation in production expenses is evidently observed through the 4.6% year-over-year (YoY) increase in the producer price index (PPI) for interventional pulmonology (IP) devices, as unveiled by the U.S. Bureau of Labor Statistics (BLS) in 2024. The upward flow is further translated to the consumer price index (CPI) for related procedures, showing a 5.5% rise, as per the Organisation for Economic Co-operation and Development (OECD).
Interventional Pulmonology Market - Growth Drivers and Challenges
Growth Drivers
- Clinical and economic benefits: Adoption in the market is amplifying notably on account of clinically proven enhancements in patient outcomes and cost efficiency. As evidence, in 2022, a study from the Agency for Healthcare Research and Quality (AHRQ) underscored the ability of early IP interventions, such as EBUS-guided biopsies, in reducing hospitalizations by 22.4%. The evaluation also unfolded the potential of IP in securing $2.2 billion in savings for the U.S. medical system over two years. Besides, in 2023, the FDA demonstrated a 35.4% improvement in diagnostic precision from bronchoscopy with integrated robots, minimizing the rate of relapse.
- Increasing efforts to improve accessibility: As both public and personal spending increase, the interventional pulmonology market gains higher traction in cash inflow. For instance, in 2023, U.S. Medicare spending on IP procedures surged by 9.4% YoY, totaling $3.6 billion. This was the result of its policy reform that expanded coverage for lung cancer screening. Further, in 2024, the government of Germany sanctioned a €1.4 billion grant to the development and deployment of IP devices to cope with the rise in nationwide COPD occurrences, as per the Federal Ministry of Health (BMG). Moreover, such financial backing is accelerating the adoption of bronchoscopy and pleural interventions across key marketplaces.
- Tech-based innovation and its global validation: The regulatory and financial support towards clinically validated technologies is an indication of accelerated progress in the interventional pulmonology market. This can be evidenced by the 2024 real-world data from the Centers for Medicare & Medicaid Services (CMS), showcasing a 45.7% reduction in COPD-related hospitalizations from the use of Pulmonx's Zephyr Valve. As a result, a 40.3% increase in FDA approvals for AI-powered bronchoscopes was observed in 2023 alone, based on their nodule detection accuracy. This is reinforcing the therapeutic value of technological innovations, securing a prosperous future for this sector.
Historical Patient Growth (2010-2020) & Its Impact on Future Market Expansion
Statistical Patient Growth Data (2010-2020)
|
Country |
2010 IP Users (Thousand) |
IP Users (2020) |
Growth (%) |
Key Driver |
|
U.S. |
1200.4 |
2800.6 |
133.7 |
Medicare expansion, lung cancer screening |
|
Germany |
450.6 |
1100.4 |
144.3 |
COPD prevalence, robotic bronchoscopy adoption |
|
France |
380.3 |
920.5 |
142.8 |
National lung health program |
|
Spain |
210.3 |
580.4 |
176.3 |
Aging population, smoking rates |
|
Australia |
95.4 |
250.8 |
163.7 |
Asbestos-related pleural disease |
|
Japan |
520.3 |
1400.4 |
169.5 |
Geriatric demand, stent innovations |
|
India |
180.5 |
950.3 |
428.5 |
Pollution-linked respiratory diseases |
|
China |
670.4 |
2300.4 |
243.4 |
Urbanization, gov’t IP infrastructure spend |
Feasible Expansion Models Shaping the Future of the Market
Data-Driven Feasibility Models
|
Model |
Region |
Revenue Impact |
Key Driver |
|
Local Manufacturing |
India |
+12.4% (2022-2024) |
Avoided 28.3% import tax on devices |
|
ASCs Partnerships |
U.S. |
+9.8% (2023) |
Medicare reimbursement for ASCs |
|
Gov’t Screening Subsidies |
Japan |
+15.3% (2021-2023) |
National lung cancer program |
Challenges
- Limited physician training and adoption: The shortage of skilled professionals is still a hurdle in the interventional pulmonology market. As evidence, in 2023, only 25.4% of pulmonologists in France performed endobronchial ultrasound (EBUS) procedures, as sufficient training infrastructure was absent, as reported by the WHO. To bridge this gap, in the same year, Boston Scientific started an initiative of training 1.5 thousand doctors in Europe, which further increased navigation bronchoscopy adoption by 20.6%, as per the findings from the European Commission (EC).
- Price competition from local manufacturers: The intensifying pressure from pricing disparity, particularly from cost-competitive domestic players, often limits the scale of expansion in the market. In this regard, the National Health Commission (NHC) revealed that Wego bronchoscopes predominantly captured an 18.4% share in China in 2024 by undercutting Olympus prices by 50.5%. However, Cook Medical addressed the issue by launching $1.3 thousand worth of disposable scopes targeting ASCs, highlighting the industry’s successful shift toward affordability.
Interventional Pulmonology Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2034 |
|
CAGR |
7.4% |
|
Base Year Market Size (2024) |
USD 3.3 billion |
|
Forecast Year Market Size (2034) |
USD 6.1 billion |
|
Regional Scope |
|
Interventional Pulmonology Market Segmentation:
Product Segment Analysis
With a 32.9% revenue share, the bronchoscopes segment is expected to dominate the interventional pulmonology market over the assessed period. This subtype, particularly the flexible models, is highly preferred for lung cancer screening due to their compliance with stringent regulatory mandates. This is also established by a report from the U.S. Preventive Services Task Force in 2023. Thus, Medicare coverage for early detection of these malignancies is benefiting the segment with a strong financial backing and adoption rate, as per the CMS. The surge in this category is further bolstered by AI integration in scopes, which reduces misdiagnosis rates by 25.3%, solidifying its position in terms of diagnostic accuracy and procedural efficiency.
Application Segment Analysis
Lung cancer is poised to account for the largest share of 28.8% in the interventional pulmonology market throughout the discussed timeframe. The importance of early diagnosis and the worldwide enlarging patient pool are the primary drivers behind its predominant captivity in this sector. The same can be exemplified by the 40.8% rise in EBUS-TBNA adoption across Europe between 2022 and 2024 due to its superior lymph node staging accuracy, as unveiled by the WHO. The segment is further propelled by $620.7 million in funding for extensive R&D on liquid biopsy as a minimally invasive alternative for these procedures, sanctioned by the National Health Institute (NIH).
End user Segment Analysis
Hospitals are estimated to lead the end user segment in the interventional pulmonology market, while capturing a 45.7% revenue share by the end of 2034. This forefront position is consolidated by the comprehensive infrastructure of these facilities that can support all types of complex pulmonary procedures. Additionally, the 24/7 critical care capabilities and availability of specialized pulmonologists make hospitals the most preferred point of care for afflicted patients. This also testified to these organizations having a central role in performing advanced diagnostic and therapeutic IP procedures, including bronchoscopies, pleural interventions, and airway stent placements, particularly for high-acuity patients.
Our in-depth analysis of the market includes the following segments:
|
Segment |
Subsegments |
|
Product |
|
|
Application |
|
|
Procedure |
|
|
End user |
|
|
Technology |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Interventional Pulmonology Market - Regional Analysis
North America Market Insights
North America is poised to retain its leadership in the global interventional pulmonology market by holding the highest share of 38.7% during the analyzed timeline. With the U.S. accounting for 90.4% of the regional revenue generation, the landscape is mostly backed by notable healthcare advances in developed countries. The region's augmentation is also driven by the 16.7 million COPD patient pool and 450.4 thousand annual bronchoscopies performed in the U.S. market. Further, the 2023 coverage expansion by Medicare for EBUS-TBNA and 2.6 million yearly lung cancer screenings solidifies the region's dominance, while highlighting its robust healthcare infrastructure and demand for advanced pulmonary care.
The U.S. dominance over the regional interventional pulmonology market is primarily gained from its ability to deliver exceptional healthcare and success in extensive clinical R&D. In addition, as evidence of a strong capital influx, in 2024 alone, Medicare allocated approximately $2.5 billion to IP procedures, according to a report from the CMS. Besides, the rapid adoption of AI bronchoscopy systems testifies to the technologically progressive atmosphere cultivated across the country, where the FDA cleared 3 new AI-assisted platforms in 2023. Currently, ASCs handle 25.6% of procedures, reflecting market diversification and the presence of greater opportunities (AHRQ).
Canada is predicted to contribute to the North America interventional pulmonology market expansion with intense cash inflow from both public and private investors. This can be evidenced by the $3.6 billion federal funding sanctioned in 2024, as reported by Health Canada. Besides, an 18.7% surge in pleural catheter adoption in Ontario also signifies the country's significance in this sector, according to the Canadian Institute for Health Information (CIHI). On the other hand, the Public Health Agency of Canada (PHAC) reported a 12.4% YoY increase in lung cancer-related IP procedures, which highlights growing clinical demand in this sector.
APAC Market Insights
The Asia Pacific interventional pulmonology market is poised to expand at the highest pace during the timeline between 2025 and 2034. The region's accelerated propagation in this sector is primarily stimulated by the rising pollution-related respiratory diseases, government screening initiatives, and increasing adoption of minimally invasive technologies. Japan augments the landscape with its strong emphasis on healthcare robotics, while South Korea and Malaysia demonstrate rapid growth in support of national insurance expansions. These factors, coupled with the success in localized manufacturing, position APAC as the global leader in establishing a progressive business environment in this field.
China dominates the APAC interventional pulmonology market with 45.6% regional share. The country's massive growth in this category originates from its global leadership in medical device manufacturing, large population, and ambitious government goals. The same can be testified by the $5.4 billion healthcare AI investments by the governing body of China in 2024, as per the National Medical Products Administration (NMPA). Further, the nationwide demography is traced through 2.2 million annual lung cancer cases, while 2.7 million COPD patients received IP care, according to the 2023 WHO report.
India is making strides in terms of adoption rate in the interventional pulmonology market through cost optimization and domestic innovation. In support of this cohort, the country's focus is highly concentrated on local stent production, which has already reduced costs by 30.7%, as reported by the Central Drugs Standard Control Organization (CDSCO). Influenced by such lucrative investment opportunities, Medtronic established a local assembly plant in Hyderabad that enables a 6-month faster market entry, according to the CDSCO report. On the other hand, Cook Medical introduced its newly developed affordable alternative, pleural catheters, which drove 30.7% adoption growth in India, as per the Indian Council of Medical Research (ICMR).
Interventional Pulmonology Market Adoption Rates
|
Country |
2023 Adoption (%) |
2024 Projection (%) |
Key Launch (Year) |
|
Australia |
45.3 |
53.4 |
Robotic bronchoscopy (2022) |
|
South Korea |
43.5 |
51.7 |
AI-guided systems (2023) |
|
Malaysia |
29.6 |
36.3 |
Disposable scopes (2024) |
Europe Market Insights
Europe is predicted to augment its position as the second-largest shareholder in the global interventional pulmonology market consistently by the end of 2034. According to the WHO, the region consists of a 40.7 million COPD patient pool, which testifies to the presence of a sustainable demand base. Additionally, the region-wide reimbursement reforms are ensuring maximum adoption in this sector by providing adequate financial backing. Alongside Germany and the UK, Italy and Spain are also presenting a strong consumer base, with a 15.6% increase in EBUS procedures from 2022 to 2024 due to national screening programs, as per the Italian Medicines Agency (AIFA).
Germany dominates the Europe interventional pulmonology market with a 32.6% share, which is primarily driven by its 10.7 million COPD cases, registered by the WHO in 2023. Besides, the Robert Koch Institute (RKI) recorded a 12.4% increase in the occurrence of this ailment in the country since 2018, which indicates the continuation of demographic expansion. Moreover, the nation's robust reimbursement system, where the G-BA covers 90.3% of EBUS procedures, is enhancing accessibility in this sector. Additionally, the €300.7 million BMG innovation fund for AI-guided bronchoscopy is accelerating the pace of innovation in this category.
The UK holds a 22.8% share in the Europe interventional pulmonology market on account of the £1.6 billion IP budget allocation by the National Health Service (NHS). The expanded lung cancer screening programs are also benefiting the sector by identifying more than 1.8 million patients annually. Besides, between 2022 and 2024, the volume of outpatient IP procedures rose by 25.9%, which also signifies the favorable epidemiological shift in the UK, as per the Association of the British Pharmaceutical Industry (ABPI). Furthermore, greater commercial success gained from ASC partnerships is propelling participation in this sector, as underscored by the NHS findings.
Interventional Pulmonology Market Adoption Rates
|
Country |
2023 Adoption (%) |
2025 Forecast (%) |
Growth Drivers |
|
Spain |
48.7 |
62.8 |
Rising lung cancer screening programs |
|
Italy |
55.3 |
68.4 |
Strong public reimbursement policies |
|
Russia |
30.4 |
42.5 |
Increasing private sector investments |
Key Interventional Pulmonology Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The commercial dynamics of the interventional pulmonology market are influenced by strategic moves of Olympus, Boston Scientific, and Medtronic, who collectively control over 55.8% of global revenue. Such leaders are increasingly integrating AI to leverage product capabilities that can solidify their forefront position in this sector for the upcoming years. On the other hand, Cook Medical and Ambu are more focused on the cultivation of a disposable pipeline that can establish a stronger alignment with infection risk-related requirements. Furthermore, pioneers in emerging landscapes, such as Vathin and Mindray, are gaining ground in this category with their innovations in cost-effective alternatives.
Such key players are:
|
Company Name |
Country |
Market Share (2024) |
Industry Focus |
|
Boston Scientific |
U.S. |
18.8% |
Advanced airway stents and navigational bronchoscopy platforms. |
|
Medtronic |
Ireland |
15.3% |
Robotic-assisted bronchoscopy and pleural intervention devices. |
|
Cook Medical |
U.S. |
10.6% |
Specializes in disposable bronchoscopes and pleural catheters. |
|
Pulmonx Corporation |
U.S. |
8.3% |
Focuses on COPD treatments like Zephyr Valves. |
|
Karl Storz |
Germany |
5.5% |
Rigid and flexible bronchoscopes for diagnostic and therapeutic procedures. |
|
Richard Wolf GmbH |
Germany |
xx% |
Advanced thoracoscopy and pleuroscopy systems. |
|
Ambu A/S |
Denmark |
xx% |
Single-use bronchoscopes for infection control. |
|
Teleflex Incorporated |
U.S. |
xx% |
Airway management devices and pleural drainage systems. |
|
Johnson & Johnson (Ethicon) |
U.S. |
xx% |
Surgical staplers and biopsy tools for lung interventions. |
|
Smiths Medical |
UK |
xx% |
Needle aspiration systems and pleural access devices. |
|
ConMed Corporation |
U.S. |
xx% |
Electrosurgical devices for lung nodule ablation. |
|
Merit Medical Systems |
U.S. |
xx% |
Balloon dilation systems for airway stenosis. |
|
Becton Dickinson (BD) |
U.S. |
xx% |
Biopsy needles and specimen collection devices. |
|
EndoChoice (now Olympus) |
U.S. |
xx% |
Disposable endoscopy solutions (acquired by Olympus). |
|
Rocket Medical |
UK |
xx% |
Pleural drainage and tracheostomy products. |
|
Vathin Medical |
India |
xx% |
Cost-effective bronchoscopes for emerging markets. |
|
Mindray Medical |
China |
xx% |
Expanding into AI-driven diagnostic bronchoscopy. |
Recent Developments
- In March 2024, Boston Scientific addressed critical infection-control needs with its EXALT Model B Single-Use Bronchoscope, targeting ICU and interventional pulmonology settings. The product saw 20.3% sales growth in Q1 2024, fueled by strong demand in Europe and Asia, as reported in the company's earnings release.
- In February 2024, Intuitive Surgical enhanced its robotic-assisted bronchoscopy platform with the Ion Endoluminal System, featuring AI-driven nodule targeting for precise lung biopsies. The advanced system drove a 15.6% increase in adoption rates across U.S. pulmonology centers by Q2 2024.
- Report ID: 7989
- Published Date: Aug 04, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Interventional Pulmonology Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
